Concurrent Use of Trelegy and Yupelri

Rationale for Avoiding Concurrent Use

The American Thoracic Society recommends avoiding concurrent use of Trelegy and Yupelri due to duplication of anticholinergic therapy, which increases the risk of adverse effects without additional clinical benefit, as Yupelri (revefenacin) is a long-acting muscarinic antagonist delivered via nebulizer 1
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines suggest that for patients with severe COPD requiring triple therapy, the combination of LABA + LAMA + ICS should be delivered as a single regimen, not duplicated across multiple devices, and adding a second LAMA (Yupelri) to existing triple therapy has no supporting evidence and violates the stepwise approach recommended by GOLD guidelines 2, 1

The American College of Chest Physicians recommends discontinuing Yupelri immediately if a patient is currently on both medications, as the umeclidinium component in Trelegy provides adequate LAMA coverage, and continuing Trelegy as the sole maintenance therapy, which provides complete triple therapy in a single once-daily inhaler 1
The European Respiratory Society suggests reassessing symptom control after 2-4 weeks, and if symptoms remain uncontrolled, considering pulmonary rehabilitation, oxygen therapy assessment, or evaluation for comorbidities rather than adding duplicate therapy 1

The British Thoracic Society recommends avoiding beta-blocking agents (including ophthalmic preparations) in all COPD patients on bronchodilator therapy, as they can antagonize the vilanterol component in Trelegy, a β2-agonist 3, 1
The American Thoracic Society suggests reviewing concurrent anticholinergic medications (including those for overactive bladder, antihistamines with anticholinergic properties) to avoid additive anticholinergic burden 3

The American College of Chest Physicians reports that Trelegy contains fluticasone furoate (ICS), which carries a 4% increased risk of pneumonia compared to bronchodilators alone, and this risk is acceptable when triple therapy is indicated (severe COPD with frequent exacerbations or blood eosinophils ≥150-200 cells/µL) 2, 1
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend monitoring for signs of pneumonia: new or worsening dyspnea, fever, increased sputum production or purulence 1

The European Respiratory Society suggests that Trelegy's once-daily Ellipta device offers superior convenience compared to nebulized Yupelri, which requires daily nebulizer setup and cleaning, and 76% of COPD patients make critical errors with metered-dose inhalers, but dry powder inhalers like Ellipta have lower error rates (10-40%) 1
The American Thoracic Society recommends that inhaler technique must be demonstrated at prescription and checked at every follow-up visit, to improve adherence and reduce errors 4, 1